Urgent Weather Update:

Winter Storm Causing Increased Emergency Department Wait Times.

117 results
Page of 10
  • HW-004 DT

    HeartWare, Inc. - A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • Ixmyelocel-T and Dilated Cardiomyopathy (STEM Cell)

    Aastrom - A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of transendocardial injection of ixmyelocel-T in subjects with heart failure due to ischemic dilated cardiomyopathy [PROTOCOL NUMBER: 55-1202-1]

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • Tafamidis Meglumine (PF-06291826) Protocol # B3461028

    Pfizer, Inc. - A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • ALN-TTRSC-004

    Alnylam Pharmaceuticals, Inc. - A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • HeartMate 3/ Momentum 3

    Thoratec Corporation - Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3™, Principal Investigator: Margarita Camacho, MD

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • The PARTNER II Trial with Registries

    Edwards Lifesciences, LLC -The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems in Intermediate and High Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery,

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PARTNER 3

    Edwards Lifesciences, LLC - A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PORTICO

    St. Jude Medical, Cardiology Division, Inc. - PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PIONEER AF-PCI

    Janssen Scientific Affairs, LLC - An open label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention.

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • Actelion Pharmaceutical ACT-293987/ Griphon 2 Double-Blind Protocol AC- 065A302

    multicenter, double-blind, placebocontrolled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension.

    • Heart and Lung Specialty Center at Toms River
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
    • Saint Barnabas Medical Center
    • Lung
  • Actelion Pharmaceutical Open-label/ Protocol AC-065A303

    a long-term singlearm open-label study to assess the safety and tolerability of ACT293987 in patients with pulmonary arterial hypertension.

    • Heart and Lung Specialty Center at Toms River
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
    • Saint Barnabas Medical Center
    • Lung
  • Actelion Pharmaceutical Prospect Registry 1-Year Study/ RTS-Epoprostenol (Flolan) Protocol AC-066A501

    a registry to prospectively describe use of Epoprostenol for injection (RTSEpoprostenol) in patients with pulmonary arterial hypertension.

    • Heart and Lung Specialty Center at Toms River
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
    • Saint Barnabas Medical Center
    • Lung
Page of 10